Detalles de la búsqueda
1.
Sequence analyses of relapsed or refractory diffuse large B-cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH-EP1 study.
Am J Hematol
; 98(4): 645-657, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36606708
2.
Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R-Mini-CYVE) regimen for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma not eligible for intensive chemotherapy.
Eur J Haematol
; 106(4): 574-583, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33512026
3.
Low risk of invasive lobular carcinoma of the breast in carriers of BRCA1 (hereditary breast and ovarian cancer) and TP53 (Li-Fraumeni syndrome) germline mutations.
Breast J
; 25(1): 16-19, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30414230
4.
Innovative therapies based on molecular orientation in patients with relapse and refractory diffuse large B-cell lymphoma: Results of LNH-EP1 study.
Am J Hematol
; 96(10): E376-E379, 2021 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34165816
5.
Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.
Eur J Cancer
; 92: 1-10, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29413684
6.
Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.
Eur J Cancer
; 84: 290-303, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28846956
Resultados
1 -
6
de 6
1
Próxima >
>>